查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198657

移植市場增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Transplantation Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計移植市場在預測期內（2022-2027 年）的複合年增長率為 9.9%。

市場增長的主要驅動力是對新型組織移植產品和器官移植治療器官衰竭的需求不斷增長。根據發表在 Current Transplantation Reports 上的一項題為“實體器官移植中 COVID-19 的診斷測試”的研究:根據 "Current Clinical Application and Future Strategies" ，2020 年 10 月，實體器官移植將受到 COVID-19 疫情的影響，包括供體和受體的適宜性、移植後感染和感染預防。此外，根據 2022 年 5 月發表在American Journal of Critical Care上的題為 "Epidemiology of Organ Failure Before and During COVID-19 Pandemic Surge Conditions" 的研究，腎衰竭是大流行期間入院時最常見的器官衰竭。衰竭是醫院中最常見的器官衰竭。在 SARS-CoV-2 陽性組中，與大流行前相比，呼吸衰竭增加了 231%。因此，隨著器官衰竭的增加，移植需求在預測期內將會增加。

此外，全球對組織器官移植，尤其是腎臟、心臟、肝臟和肺移植的需求非常高。器官衰竭是由多種因素引起的，包括不良飲食、過度飲酒、缺乏運動和藥物濫用。因此，對植入式產品的需求預計將很快增加。器官捐獻的增加是研究中市場增長的最重要因素之一。根據器官獲取組織協會（AOPO）2021 年 1 月公佈的數據，2020 年有超過 12500 人捐獻了一個或多個器官，比上一年增加了 6%。此外，2020年已故器官捐獻者數量達到3.65萬多件，比上年增長約2%。這些摘取的器官挽救了超過33,000條生命，連續第七年超過上年。心血管死後捐贈（DCD）也有所增加，超過 3,000 人，同比增長 18%。

此外，癌症、心臟和腎臟疾病等慢性病患病率的增加正在推動市場增長。例如，國際腎髒病學會 (ISN) 和國際腎臟基金會聯合會 (IFKF) 聯合倡議的 2020 年 3 月世界腎臟日發布的數據表明，腎臟疾病影響著全球約 8.5 億人。此外，根據全球癌症觀察站發布的全球185個國家36種癌症的發病率和死亡率估算的Globocan 2020報告顯示，2020年將有19,292,789名新確診癌症患者，19,292,789人將死於癌症. 估計約為 9,958,133。

此外，主要市場參與者的產品發布以及併購等市場參與者採取的各種策略預計將在預測期內提振市場。例如，2021 年 6 月，移植診斷公司 CareDx 收購了總部位於紐約的 Transplant Hero，這是一家旨在支持移植患者需求的智能手機應用程序開發商。由於主要市場參與者的這些努力，植入產品將變得更容易獲得併幫助市場增長。

因此，上述所有因素都有望在預測期內提振市場。然而，器官捐獻者短缺以及倫理和文化問題是預測期內市場的製約因素。

移植市場趨勢

預計紙巾產品領域將在預測期內主導市場

組織捐贈是從一個人身上取出身體組織（皮膚、角膜、骨骼等）並將其移植到另一個人身上。該細分市場的擴張與移植手術的增加有關，例如人工耳蝸、心臟瓣膜、骨髓和矯形軟組織。

根據 Organ Procurement Organization Association 2022 年 3 月的一份報告，每年約有 30,000 名組織捐獻者為超過 175 萬次挽救生命和挽救生命的組織移植做出貢獻。因此，預計在預測期內增加組織移植將提振市場。

移植技術的進步和製造商推出的新產品預計將推動移植手術的數量，包括腎臟、肝臟、心臟、肺和組織移植。例如，2021 年 7 月，Bioventus Inc. 宣布推出 OSTEOAMP，這是一種流體同種異體移植骨替代解決方案，專為包括腰椎、頸椎和足/踝融合手術在內的多種患者手術而開發。推出了 SELECT Flowable。

此外，合作夥伴關係、併購正在支持市場的擴張。例如，2022 年 5 月，Orthofix Medical 與 MTF Biologics 續簽並擴大了合作協議。該合作夥伴關係將 Orthofix 對 Trinity 同種異體移植線的獨家商業權利擴展到 2032 年，還包括擴大協議以開發脫礦骨基質（ DBM ）， Orthofix 將以 Legacy 品牌名稱銷售。

因此，所有上述因素預計將在預測期內推動該部門的增長。

北美主導市場，預計在預測期內也會如此。

北美在移植診斷市場佔有主要份額，預計在預測期內將保持相同的增長速度。

美國和加拿大等國家通過資金充足的機構、基礎設施和政府參與創造了現金和意識，以鼓勵患者進行器官移植。例如，根據美國國立衛生研究院2021年6月的數據，2018年、2019年和2020年用於移植研究的經費將分別達到6.5億美元、7.33億美元和7.21億美元。據說有因此，增加對移植研究的資助將導致移植利用的增加，推動該地區的市場增長。

此外，根據衛生資源服務局的數據，到 2022 年 2 月，美國實體器官移植的國家移植等待名單上將有超過 106,000 人。實體器官移植候補名單的百分比為腎臟（83%）、肝臟（11%）、胰腺（1%）、心臟（3%）、肺（%）和其他（2%）。預計對實體器官的需求增加將導致對該細分市場的測試增加，從而在預測期內推動該細分市場的增長。根據2022年2月公佈的器官捐獻統計數據，2021年美國將進行4萬多例器官移植。因此，在預測期內，移植的增加將推動該市場的增長。

預計慢性病患病率上升將在預測期內提振市場。美國癌症協會估計，到 2022 年，美國將有大約 79,000 例腎癌新病例，約有 13,920 人死於該病。根據同一消息來源，腎癌是男性和女性最常見的 10 種癌症之一。總體而言，男性一生中患腎癌的風險約為四分之一 (2.02%)。女性的終生風險約為 80 分之一 (1.03%)。

預計主要市場參與者增加產品發布將在預測期內提振市場。例如，2021 年 7 月，Orathofix Medical Inc. 推出並推出了首款帶有 fiberFUSE Strip 的患者植入物，這是一種先進的脫礦纖維骨移植溶液，含有鬆質骨。

世界上很大一部分人口正在接近這兩個國家以尋找更好的醫療保健設施，因此該地區非常有利於增長，並在預測期內研究的市場中佔有很大份額。預計將佔據

移植市場競爭者分析

市場高度分散，有許多大、中、小型供應商。併購幫助供應商擴展他們現有的產品組合和地理範圍。參與者參與新產品發布、併購和區域擴張，以獲取行業中最大的收入份額。該行業的主要參與者包括 Abbvie, Inc、Arthrex, Inc、Zimmer Biomet、Medtronic、Novartis AG 和 Strykers。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

目錄

第 1 章 簡介

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第三章執行摘要

第四章市場動態

  • 市場概況
  • 市場驅動力
    • 慢性病負擔加重
    • 增加器官衰竭的負擔
    • 移植技術進步
  • 市場製約因素
    • 器官捐獻者短缺
    • 倫理和文化問題
  • 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭對手之間的競爭

第 5 章市場細分（基於價值的市場規模:百萬美元）

  • 按產品
    • 紙巾產品
    • 免疫抑製劑
    • 保存液
  • 按申請
    • 器官移植
    • 組織移植
  • 按最終用戶
    • 醫院
    • 移植中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 歐洲其他地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 亞太其他地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 中東其他地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美地區

第六章競爭格局

  • 公司簡介
    • Abbvie, Inc
    • Arthrex, Inc.
    • Zimmer Biomet
    • Medtronic
    • Novartis AG
    • Strykers
    • 21st Century Medicine
    • BiolifeSolutions, Inc
    • Teva Pharmaceuticals
    • Orthofix Medical
    • Veloxis Pharmaceutical
    • Amnio Technology

第七章市場機會與未來趨勢

簡介目錄
Product Code: 90826

The Transplantation Market is expected to register a CAGR of 9.9% during the forecast period (2022-2027).

A major factor driving market growth is the rising demand for novel tissue transplantation products and organ transplantation to treat organ failure. According to the study published in Current Transplantation Reports, titled 'Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies' in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. Moreover, according to the study titled "Epidemiology of Organ Failure Before and During COVID-19 Pandemic Surge Conditions," published in the American Journal of Critical Care in May 2022, during the pandemic, renal failure was the most common type of organ failure at admission and respiratory failure was the most common type of hospital-onset organ failure. The SARS-CoV-2-positive group showed a 231% increase in respiratory failure compared with the pre-pandemic group. Thus, with increasing organ failure, the demand for transplantation increases over the forecast period.

Moreover, the global demand for tissue and organ transplantation, particularly kidney, heart, liver, and lung transplantation, is extremely high. Organ failure is caused by a variety of factors, including poor dietary habits, excessive alcohol consumption, a lack of exercise, and drug abuse. As a result, transplantation product demand is expected to increase shortly. The rising donation of organs is one of the biggest contributors to the growth of the market studied. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, an increase of almost 2% year over year. For the seventh year in a running, these retrieved organs saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in Donation after Circulatory Death (DCD) contributions, which totaled more than 3,000 donors, up 18% year over year.

Furthermore, rising in the prevalence of chronic diseases such as cancer and heart and kidney diseases is propelling the growth of the market. For Instance, in March 2020, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850 million people globally. In addition, as per the Globocan 2020 report published by Global Cancer Observatory, which estimated the incidence and mortality of 36 cancer in 185 countries globally, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020, and about 9,958,133 people died due to cancer.

Additionally, product launches by the key market players, as well as various strategies adopted by the market players such as mergers and acquisitions, are anticipated to boost the market over the forecast period. For Instance, in June 2021, transplant diagnostics company CareDx acquired New York-based Transplant Hero, the developer of a smartphone app that's aimed at supporting the needs of transplant patients. As a result of such initiatives by key market players, the transplantation product becomes more accessible, boosting the market growth.

Thus, all aforementioned factors are anticipated to boost the market over the forecast period. However, the shortage of organ donors and ethical and cultural issues restraint the market over the forecast period,

Transplantation Market Trends

Tissue Product Segment is Expected to Dominate the Market Over the Forecast Period

Tissue donation is when tissues in the body (e.g., skin, corneas, bone) are removed from one person and transplanted into another person. The expansion of the segment is related to the increasing number of transplantation procedures such as cochlear, heart valves, bone marrow, and orthopedic soft tissues.

According to the Association of Organ Procurement Organization report in March 2022, Approximately 30,000 tissue donors contribute over 1.75 million life-saving and life-improving tissue transplants each year. Thus, increasing tissue transplantation is expected to boost the market over the forecast period.

Advancement in transplantation technology and the launch of new products by manufacturers is expected to propel the number of transplant procedures, including kidney, liver, heart, lungs, and tissues. For instance, in July 2021, Bioventus Inc. launched OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures, including lumbar spine fusion, cervical spine fusion, and foot & ankle fusion.

Furthermore, partnerships, mergers, and acquisitions are supporting market expansion. For instance, in May 2022, Orthofix Medical renewed and expanded its partnership agreement with MTF Biologics. The collaboration extends Orthofix's exclusive marketing rights to the Trinity allograft line through 2032 and includes an expansion agreement to develop a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.

Thus, all aforementioned factors are anticipated to boost the segment growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to hold a major share in the transplant diagnostics market and is expected to continue at the same pace over the forecast period.

Countries such as the United States and Canada have well-funded organizations, infrastructure, and government involvement in generating cash and creating awareness to encourage organ transplantation for patients. For instance, according to the National Institute of Health in June 2021, the fundings for the research in transplantation were USD 650 million, USD 733 million, and USD 721 million in 2018, 2019, and 2020 respectively. The rise in funding for transplantation research will therefore lead to increased utilization of transplants driving the growth of the market in this region.

Furthermore, according to the Health Resources and Services Administration, in February 2022, there will be over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant includes Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period. In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

The rising prevalence of chronic diseases is anticipated to boost the market over the forecast period. According to the estimates of the American Cancer Society, in 2022, there were around 79,000 new cases of kidney cancer in the United States and approximately 13,920 deaths from this disease. As per the same source, kidney cancer is among the ten most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%).

Increasing product launches by the key market players are anticipated to boost the market over the forecast period. For instance, in July 2021, Orathofix Medical Inc. launched and first patient implants with the fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.

With a large section of the population across the world approaching these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and expected to hold a significant share in the market studied over the forecast period.

Transplantation Market Competitor Analysis

The market is highly fragmented, with the presence of many large, small, and medium-scale vendors. Mergers and acquisitions support vendors in expanding their existing product portfolio and geographical reach. The players are involved in launching new products, mergers & acquisitions, and regional expansion to gain maximum revenue share in the industry. Some of the major players in the industry are Abbvie, Inc., Arthrex, Inc., Zimmer Biomet, Medtronic, Novartis AG, and Strykers.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Chronic Diseases
    • 4.2.2 Increasing Burden of Organ Failure
    • 4.2.3 Technological Advancement in Transplantation Method
  • 4.3 Market Restraints
    • 4.3.1 Shortage of Organ Donors
    • 4.3.2 Ethical and Cultural Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Tissue Products
    • 5.1.2 Immunosuppressive Drugs
    • 5.1.3 Preservation Solution
  • 5.2 By Application
    • 5.2.1 Organ Transplantation
    • 5.2.2 Tissue Transplantation
  • 5.3 By End Use
    • 5.3.1 Hospitals
    • 5.3.2 Transplant Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie, Inc
    • 6.1.2 Arthrex, Inc.
    • 6.1.3 Zimmer Biomet
    • 6.1.4 Medtronic
    • 6.1.5 Novartis AG
    • 6.1.6 Strykers
    • 6.1.7 21st Century Medicine
    • 6.1.8 BiolifeSolutions, Inc
    • 6.1.9 Teva Pharmaceuticals
    • 6.1.10 Orthofix Medical
    • 6.1.11 Veloxis Pharmaceutical
    • 6.1.12 Amnio Technology

7 MARKET OPPORTUNITIES AND FUTURE TRENDS